PCT

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

PyroGenesis Announces Acquisition of Intellectual Property Rights Related to the PUREVAPᵀᴹ Nano Silicon Reactor and Nano-Silicon Development

Retrieved on: 
Tuesday, March 26, 2024
PCT, GHG, FRA, 0 A.D. (video game), Pollution, Silicon, TSX, ARC, Patent, Greenhouse

The PUREVAP™ NSiR is a proprietary process, originally designed and developed by PyroGenesis on behalf of HPQ Nano Silicon Powders Inc. (“HPQ Nano”), a wholly-owned subsidiary of HPQ Silicon, that can use different purities of silicon (Si) as feedstock to make a wide range of spherical silicon nano- and micro-powders and wires, for potential use across various applications including as a potential replacement metal in lithium-ion batteries.

Key Points: 
  • The PUREVAP™ NSiR is a proprietary process, originally designed and developed by PyroGenesis on behalf of HPQ Nano Silicon Powders Inc. (“HPQ Nano”), a wholly-owned subsidiary of HPQ Silicon, that can use different purities of silicon (Si) as feedstock to make a wide range of spherical silicon nano- and micro-powders and wires, for potential use across various applications including as a potential replacement metal in lithium-ion batteries.
  • Under the terms of a 2020 Development and Purchase Agreement between PyroGenesis and HPQ Nano, all rights in the PUREVAP NSiR process (including any intellectual property rights) were assigned to HPQ Nano on condition that should HPQ Nano choose not to commercialize the technology, PyroGenesis would have the option to have the ownership of this technology revert back to it at no additional cost.
  • “Nano silicon is still in its infancy, and so is the understanding of its usefulness.
  • Reacquiring the intellectual property related to the PUREVAP NSiR allows us to continue to explore the full spectrum of possibilities for this metal,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 12, 2024
The Orange Book, Patent Cooperation Treaty, Agitation, Administration, Conference call, Type, PCT, Conference, Database, Schizophrenia, Intelligence, Caregiver, Webcast, Patient, DSM-IV codes, Neuroscience, Fast Track, Food and Drug Administration, CMC, Wind, Orange Book, SCNC, Positive, Microsatellite instability, Dexmedetomidine, Clinical trial, Therapy, Safety, Patent, Research and development, Collection, FDA, Approved drug, Dementia, CAD, Food, Pharmaceutical industry

NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • In addition, the Company reported its financial results for the fourth quarter and full year 2023.
  • Net Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  • Net Loss: BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
  • ET to provide an update on recent operational highlights and to discuss its fourth quarter and full year 2023 financial results.

Guangdong Province Advances Modernization with Focus on Quality Development

Retrieved on: 
Monday, April 1, 2024
Sustainability, Environmental Health, Public Transport, Public Policy, Environment, Construction & Property, Other Transport, Urban Planning, Automotive Manufacturing, Transport, Manufacturing, Government, State Council, PCT, Silver, Information, Economic development, Carbon, Biodiversity, Wang, GDP, NEV, Multimedia, Creative industries

At the "High-Quality Development" press briefing on March 29th, 2024, hosted by the Information Office of the State Council of China, Guangdong Province Governor Wang Weizhong detailed the region's strategies for achieving high-quality development, highlighting their role in driving the province's modernization efforts.

Key Points: 
  • At the "High-Quality Development" press briefing on March 29th, 2024, hosted by the Information Office of the State Council of China, Guangdong Province Governor Wang Weizhong detailed the region's strategies for achieving high-quality development, highlighting their role in driving the province's modernization efforts.
  • (Photo: Business Wire)
    Wang discussed Guangdong's approach to integrating modern development practices with local characteristics, emphasizing the importance of technological innovation and industrial growth in improving development quality.
  • Environmental sustainability and public welfare have also been areas of focus for Guangdong.
  • The province has reported improvements in air quality and forest coverage, alongside efforts towards carbon neutrality and enhancing biodiversity.

Practicing High-quality Development and Promoting Modernization in Guangdong Province

Retrieved on: 
Tuesday, April 2, 2024
Employment, State Council, PCT, Environment, Tunnel, Social Security, Information, Pearl River Delta, Carbon, City, GDP, Intellectual property

Wang Weizhong, Governor of Guangdong Province, introduced the economic and social development of Guangdong around the theme of "Promoting High-quality Development of Guangdong and Advancing Modernization with Chinese Characteristics".

Key Points: 
  • Wang Weizhong, Governor of Guangdong Province, introduced the economic and social development of Guangdong around the theme of "Promoting High-quality Development of Guangdong and Advancing Modernization with Chinese Characteristics".
  • Wang Weizhong said that Guangdong has actively advanced the construction of modernization with Chinese characteristics around the primary task of high-quality development as well as the strategic task of building a new development pattern.
  • Guangdong is a province with an enormous economy, a large population and a huge foreign trade.
  • Guangdong relies on productivity of new quality to inject strong vitality into high-quality development.

Inside information: Bioretec's RemeOs™ biodegradable magnesium alloy composition has been allowed a patent by the U.S. Patent office

Retrieved on: 
Thursday, March 21, 2024
PCT, CE, Patient, Trauma, Health care, IPR, Patent, USD, EET

TAMPERE, Finland, March 21, 2024 /PRNewswire/ -- Bioretec Ltd., a pioneer in biodegradable orthopedic implants, has been allowed a patent by the U.S. patent office for its RemeOs™ magnesium alloy composition. The U.S. patent office will grant and publish the patent after the Company's confirmation.

Key Points: 
  • Bioretec Ltd Inside information 21 March 2024 at 7:00 p.m. EET
    TAMPERE, Finland, March 21, 2024 /PRNewswire/ -- Bioretec Ltd., a pioneer in biodegradable orthopedic implants, has been allowed a patent by the U.S. patent office for its RemeOs™ magnesium alloy composition.
  • The U.S. patent office will grant and publish the patent after the Company's confirmation.
  • Allowed patent concerns RemeOs™ magnesium-calcium-zinc alloy composition for orthopedic implants[1].
  • The patent also includes the usage of the RemeOs™ magnesium alloy in the manufacturing of orthopedic implants or a part of such implants for all patient populations.

Inside information: Bioretec's RemeOs™ biodegradable magnesium alloy composition has been allowed a patent by the U.S. Patent office

Retrieved on: 
Thursday, March 21, 2024
PCT, CE, Patient, Trauma, Health care, IPR, Patent, USD, EET

TAMPERE, Finland, March 21, 2024 /PRNewswire/ -- Bioretec Ltd., a pioneer in biodegradable orthopedic implants, has been allowed a patent by the U.S. patent office for its RemeOs™ magnesium alloy composition. The U.S. patent office will grant and publish the patent after the Company's confirmation.

Key Points: 
  • Bioretec Ltd Inside information 21 March 2024 at 7:00 p.m. EET
    TAMPERE, Finland, March 21, 2024 /PRNewswire/ -- Bioretec Ltd., a pioneer in biodegradable orthopedic implants, has been allowed a patent by the U.S. patent office for its RemeOs™ magnesium alloy composition.
  • The U.S. patent office will grant and publish the patent after the Company's confirmation.
  • Allowed patent concerns RemeOs™ magnesium-calcium-zinc alloy composition for orthopedic implants[1].
  • The patent also includes the usage of the RemeOs™ magnesium alloy in the manufacturing of orthopedic implants or a part of such implants for all patient populations.

EQS-News: Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Retrieved on: 
Wednesday, March 13, 2024
AMSilk, Protein engineering, A-DNA, AI, Research and development, Molecular biology, PCT, Gold, Gel, Microplastics, CO2, BRAIN, Partnership, Fine chemical

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

Key Points: 
  • Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
    The issuer is solely responsible for the content of this announcement.
  • Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
    Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading provider of solutions for the biologization of industry, and AMSilk GmbH, a global leader in advanced materials made from spider silk-based proteins, announce the successful completion of the first phase of a development collaboration.
  • The success of this strategic R&D collaboration is based on the use of BRAIN Biotech’s rational design in protein engineering.
  • With their years of protein engineering expertise and with our common vision, BRAIN Biotech is an ideal fit as a development partner.”

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Central nervous system, Obesity, Patent, PCT, Patent Cooperation Treaty, MDMA, DSM-IV codes, Pharmaceutical industry

Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted three additional patent applications under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • In addition, seven patent applications were filed under the international PCT.
  • Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer, stated, “These latest patent applications are expected to significantly expand our IP protection, and further enhance our leadership in the psychedelic space.

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Central nervous system, TEL, Obesity, Ketamine, Patent, Ibogaine, PCT, Patent Cooperation Treaty, MDMA, PEA, CWY, Disorder, DSM-IV codes, Pharmaceutical industry

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
  • In addition, seven applications were filed under the PCT.